NEW YORK (GenomeWeb News) – Coverage of Foundation Medicine was initiated today by Goldman Sachs and Leerink Swann, which gave the cancer genomics analysis firm a Neutral and Outperform rating, respectively.

Goldman Sachs gave the company a six-month share target price of $33, while Leerink Swann gave it a $39 price target. The two investment banks were underwriters in Foundation's initial pubic offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.